TABLE 1

Crude and Laboratory Confirmation–Adjusted HZ Incidence Rates by Selected Demographic and Clinical Characteristics, 2003–2014

CharacteristicsNo. Children in the Study PopulationPerson yHZ CasesIncidence Rates (Crude) per 100 000 Person yProportion KPNW Study Participants Positive for VZV by PCR per No. Adequate Specimens (N = 309), n (%)aIncidence Rates (Adjusted) per 100 000 Person y (95% CI)
Sexb
 Male3 232 0969 864 319689470120 of 155 (77.4)54 (41–70)
 Female3 139 6099 449 629748979134 of 154 (87.0)69 (54–87)
Immunocompromised
 Yes31 65565 6692714134 of 5 (80.0)330 (295–368)
 No6 340 41219 248 70214 12273250 of 305 (82.2)60 (46–77)
Vaccination status
 Unvaccinated3 185 3355 311 4569044170174 of 194 (89.7)153 (128–179)
 Vaccinated3 186 73214 002 91553393880 of 115 (69.6)27 (17–39)
Site
 A468 3731 061 8931296122254 of 309 (82.2)100 (81–122)
 B395 715944 341991105254 of 309 (82.2)86 (69–106)
 C136 481487 965492101254 of 309 (82.2)83 (66–102)
 D2 241 5797 463 212486665254 of 309 (82.2)54 (41–70)
 E378 400968 2301010104254 of 309 (82.2)86 (69–106)
 F2 751 5198 388 730572868254 of 309 (82.2)56 (42–73)
Age group, y
 1–2N/A1 872 7757634125 of 32 (78.1)32 (22–45)
 3–9N/A7 373 89529434038 of 56 (67.9)27 (18–39)
 10–17N/A10 067 70110 677106191 of 221 (86.4)92 (74–113)
All subjects6 372 06719 314 37114 38374254 of 309 (82.2)61 (47–78)
  • CI, confidence interval; N/A, not applicable.

  • a These laboratory confirmation proportions were calculated for each category from the Weinmann et al7 study at KPNW. The overall proportion, calculated by combining the previous study’s vaccinated and unvaccinated groups, was applied to each of the site-specific groups.

  • b Reported numbers of boys and girls omit 362 children without documented sex.